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Bioenergetics of cancer☆Cancer research has inspired the ﬁeld of bioenergetics and
mitochondrial physiology with the recent discovery of Kreb's cycle
intermediates involved in the regulation of cancer genes essential for
tumor survival or the discovery of the role of p53 in the assembly of
cytochrome c oxidase via SCO2. Innovative strategies of bioenergetic
cancer medicine will emanate from this basic knowledge and the ﬁrst
step consists in the understanding of the modalities of cancer cell
energy production. How do cancer cells derive their energy from the
accessible carbon sources and what are the preferential energy
substrates and processing pathways used for tumor growth?
Cancer cell bioenergetics is mainly determined by a complex
interplay among cancer genetics, microenvironment and immunity.
Molecular studies have provided new evidence for a variable
bioenergetic signature of human tumors in contrast with the dogmal
Warburg theory. Within tumors, cancer cells can even use lactate via
oxidative phosphorylation to produce energy. These studies empha-
size the need for tumor bioenergetic proﬁling prior to apply
designated and personalized metabolic medicine.
In this special issue of BBA Bioenergetics on “Cancer Bioenergetics”
we regrouped 25 articles on tumor bioenergetics andputativemetabolic
anti-proliferative strategies.We present ﬁrst the particularities of cancer
energetics and we discuss some key regulatory mechanisms of tumor
catabolism and anabolism. Such mechanisms include for instance the
post-transcriptional modiﬁcation of the mitochondrial F1F0-ATP
synthase, or the activation of ANT2 and of UCP2 during carcinogenesis.
We explain how the bioinformatics modeling of cancer energy
production could allow to identify the controlling steps of ATP
production. Besides bioenergetic proﬁling, we present the interaction
between cancer energy production and intracellular signaling associated
with carcinogenesis. For instance, we explain the role of NOX1 in ROS-
signaling and tumor growthor the importance ofmitochondrial proteins
HtrA2 and HINT2 in the (de) regulation of apoptosis. We further
examined the role of mutations in mitochondrial DNA on the
susceptibility to cancer. Conversely, we considered the impact of cancer☆ This article is part of a Special Issue entitled: Bioenergetics of Cancer.
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doi:10.1016/j.bbabio.2011.03.005epigenomic and genomic changes on mitochondrial bioenergetics. The
last part of this special issue concerns the interaction between bioactive
food components and cancer energetics as well as the design of
innovative metabolic approaches for cancer-killing.
To conclude, these are exciting times in the ﬁeld of tumor
bioenergetics and this special issue reﬂects the recent advances in
basic science that will support the development of anti-cancer
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